Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106 USD | -0.24% | -0.80% | -3.70% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.70% | 184B | |
-2.14% | 107B | |
-4.49% | 67.52B | |
+1.03% | 50.06B | |
+9.98% | 45.67B | |
+3.40% | 41B | |
+3.79% | 26.73B | |
+4.13% | 26.47B | |
+15.23% | 25.05B | |
-3.01% | 24.56B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Raymond James Raises Abbott Laboratories' Price Target to $124 From $110, Maintains Outperform Rating